Agents targeting pentraxins, such as PTX3 inhibitors, are being explored for their potential to modulate inflammation and reduce cardiovascular risk in patients with CKD.133 Therapeutic targeting of Damage-Associated Molecular Patterns associated with CKD also appears to be a promising strategy to reduce chronic vascular inflammation and cardiovascular risk.134. The gene discussed is PTX3; the disease is chronic kidney disease.